Starpharma Holdings Limited

Starpharma Holdings Ltd (ASX:SPL)(OTCQX:SPHRY) recently announced the Company's most important commercial milestone to date with the signing of a full license agreement with SSL International for the development of the VivaGel(R)-coated condom. SSL manufactures and markets Durex(R), the world's number one condom.

Starpharma Holdings Ltd (ASX:SPL)(PINK:SPHRY) today announced new data showing that SPL7013, the active ingredient in its topical microbicide VivaGel(R), inhibits all four strains of the human papillomavirus (HPV) targeted by the two marketed cervical cancer vaccines.

Attached is the Chairman's address to the Annual General Meeting of Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY), to be held at 4.00pm today.

Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) today announced that one of its key patents relating to the use of dendrimers to protect against sexually transmitted infections has been approved in Japan.

Starpharma Holdings Limited (ASX:SPL)(PINK:SPHRY) today announced that a full licence agreement has been signed with SSL International plc (LSE:SSL) in relation to the VivaGel(R) coated condom. SSL manufactures and sells Durex(R) condoms, the market-leading condom brand worldwide.

Starpharma Holdings Limited (ASX:SPL)(PINK:SPHRY) today announced its full year financial results for the year ended 30 June 2008.

Starpharma Holdings Limited (ASX:SPL)(PINK:SPHRY) today announced the start of its next clinical trial of VivaGel(R). The study will measure the level of antiviral activity retained by VivaGel(R) after vaginal administration. Assessment will be by laboratory assay of vaginal samples collected up to 24 hours after VivaGel(R) application. The study in 12 women will determine the timescale over which VivaGel(R) retains activity against HIV and HSV-2 (genital herpes).

Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) today announced that it will add the treatment of bacterial vaginosis (BV) to the development program for its vaginal microbicide VivaGel(R).

Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) today announced positive results of a clinical trial that achieved all its objectives demonstrating that 3% SPL7013 Gel (VivaGel(R)) was safe and well-tolerated in sexually abstinent women when administered vaginally, twice daily for 14 days.

Starpharma Holdings Ltd (ASX:SPL)(OTCQX:SPHRY) has been advised that all of the Company's shares held by ANZ pursuant to stock lending arrangements associated with the Opes Prime Group have now been sold in an orderly fashion.